This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nichi-Iko Pharmaceutical Valuation

Is 4541 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4541 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4541's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4541's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4541?

Key metric: As 4541 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4541. This is calculated by dividing 4541's market cap by their current revenue.
What is 4541's PS Ratio?
PS Ratio	0.1x
Sales	JP¥182.88b
Market Cap	JP¥24.64b

4541 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	-2.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 4541's PS Ratio compare to its peers?

The above table shows the PS ratio for 4541 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.7x
4577 Daito PharmaceuticalLtd	0.7x	7.1%	JP¥32.5b
4548 Seikagaku	1.1x	n/a	JP¥44.1b
4554 Fuji Pharma	0.8x	7.0%	JP¥36.6b
8095 Astena Holdings	0.4x	n/a	JP¥19.8b
4541 Nichi-Iko Pharmaceutical	0.1x	n/a	JP¥24.6b

Price-To-Sales vs Peers: 4541 is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.6x).

Price to Sales Ratio vs Industry

How does 4541's PS Ratio compare vs other companies in the JP Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	1.9x	4.7%
4541 Nichi-Iko Pharmaceutical	0.1x	n/a	US$185.57m
8095 Astena Holdings	0.4x	n/a	US$128.54m
4539 Nippon Chemiphar	0.2x	n/a	US$35.38m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap
Industry Avg.	1.9x	11.7%
4541 Nichi-Iko Pharmaceutical	0.1x	n/a	US$185.57m

No more companies

Price-To-Sales vs Industry: 4541 is good value based on its Price-To-Sales Ratio (0.1x) compared to the JP Pharmaceuticals industry average (1.8x)

Price to Sales Ratio vs Fair Ratio

What is 4541's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4541 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4541's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Tsumura

JP¥360.8b

Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.

4540

JP¥4,836.00

-1.7%

73.5%

Shionogi

JP¥1.8t

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.

4507

JP¥2,140.50

2.3%

-7.7%

Daito PharmaceuticalLtd

JP¥32.6b

Manufactures and sells pharmaceutical products worldwide.

4577

JP¥2,121.00

1.1%

8.0%